Monogram Orthopaedics, Inc.

NasdaqCM MGRM

Monogram Orthopaedics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -4,456.87%

Monogram Orthopaedics, Inc. Operating Income Margin is -4,456.87% for the Trailing 12 Months (TTM) ending September 30, 2024. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
  • Monogram Orthopaedics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -561,188.89%, a -40,145.33% change year over year.
  • Monogram Orthopaedics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,394.42%.
Key data
Date Operating Income Margin EBT Margin Net Income Margin EBITDA Margin
Market news
NasdaqCM: MGRM

Monogram Orthopaedics, Inc.

CEO Mr. Benjamin Sexson C.F.A.
IPO Date May 18, 2023
Location United States
Headquarters 3913 Todd Lane
Employees 28
Sector Technology
Industries
Robotics Biotechnology
Description

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.

StockViz Staff

January 16, 2025

Any question? Send us an email